NEWS PROVIDED BY
Leonhardt Ventures LLC
30th Mar, 2023, 9:00am PT
Mission Viejo, CA , March 30th, 2023 /PRDistribution/ — Leonhardt Ventures LLC announces today that Brian Lasater has joined earlier this year the firm as Chief Technology Officer. In this role, he is responsible for implementation of the overall technology strategy, product development, rapid prototyping and product testing that empower Leonhardt Venture’s mission of harnessing the convergence of bioelectric controlled protein expressions and biologics for organ regeneration, healing, longevity and wellness.
“We are pleased to welcome Brian to join our Leonhardt Ventures team. Brian is an innovator approaching 40 years experience in medical device technologies. His life work in developing implantable devices, stimulators and non-invasive therapeutic devices provide a solid foundation to help us fulfill our mission.* said Howard J. Leonhardt, Executive Chairman & CEO
“As we position multiple products for strategic commercialization partnerships, Brian’s extensive experience in overseeing Medtech product launches and his ability to innovate and rapidly implement new product improvements based on real world marketplace feedback will be an incredible asset to Leonhardt Ventures LLC and our portfolio of startups.”
Brian Lasater brings over 38 years of Medtech product development experience to Leonhardt Ventures, specializing in innovation, transformation, strategy and growth. Over his long career he has contributed greatly to the successful launch of multiple medical products for implementations in cardiac stimulation, heart failure, stroke, hearing loss, vision loss, incontinence, sleep apnea and more. Brian spent many years with the Alfred Mann Foundation in Los Angeles. He helped develop products for Advanced Bionics, Boston Scientific, NanoStim now Abbott St. Jude, NeuroPace, Qualion and Second Sight.
“It is an incredible honor to be invited to join such a passionate and purposeful team,” Lasater says. “Leonhardt Venture’s mission to apply the convergence of bioelectric protein expressions and biologics to organ regeneration, healing, longevity and wellness, to improve and extend the lives of millions – is inspiring, but it’s even more exciting to realize with a first hand look at the data that it’s absolutely achievable. By innovating and leveraging this core technology platform in the right way, we can change the path of health and wellness by rejuvenating people in closer alignment of how they are built in the first place, with bioelectric signaling instructions and biologics.”
Leonhardt Ventures is highly focused in applying its core platform technology base in bioelectric and biologics in these key areas:
- Heart & Cardiovascular. 2. Brain Neuroscience. 3. Cosmetic and Personal Care. 4. Major Organ Regeneration and 5. Cancer.
See link to Development Pipeline here > https://leonhardtventures.com/development-pipeline/
Brian Lasater will serve as Chief Technology Advisor and Lead Engineer for a number of the innovation development teams and startups within the Leonhardt Ventures LLC portfolio, especially in their early stages of development.
The team has over 700 related patent claims issued, pending, licensed, optioned or in process https://patents.justia.com/inventor/howard-j-leonhardt
For more information on Leonhardt Ventures LLC visit www.leonhardtventures.com
About Leonhardt Venture LLC
Leonhardt Ventures LLC was founded in 1982 (formerly HJ Leonhardt & Co.) now celebrating its 40th anniversary in Medtech innovations. In the 1980’s the team pioneered development of the PolyCath line of cardiovascular balloon catheters. In the 1990’s the TALENT stent graft and StentValve. Since 2000, the team has focused on applying the convergence of bioelectrics and biologics to organ regeneration, healing, longevity and wellness. In 2001, Leonhardt led the team that completed the first non-surgical muscle cell repair of a human heart. Over 600,000 patients have used Leonhardt inventions to date. Leonhardt Ventures LLC opened Leonhardt’s Launchpads, a Life Sciences R&D Lab Incubator network, in 2008 to help support development of innovations. The primary charter mission of this R&D incubator was to explore if the research the Leonhardt team had done to regenerate hearts would apply to other organs and purposes. In 2013, it formed Cal-X Stars Business Accelerator, Inc., a mentorship based innovation and startup launch accelerator, that focuses on helping inventions to mature to a level strong enough to attract investment, patent licenses or a strategic commercialization partnership. In 2022, it formed Lionheart Health, Inc. to initially focus on commercializing select products in the area of aesthetics, longevity, wellness and sports/fitness medicine, the primarily products sought by the high growth market of Longevity & Wellness MedSpas. There are over 22,000 Wellness MedSpas today in the USA with that number expected to grow to over 30,000 by the end of this decade. Lionheart Health is committed to be their go to technology partner.
Contact: Brian Hardy, Director of Marketing, [email protected]